Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion
The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted ...
Pfizer Expects 2025 Adj. EPS Operational Growth Of 10% To 18%; Reaffirms 2024 Guidance
Pfizer (PFE) issued its full-year 2025 guidance and reaffirmed full-year 2024 guidance. Pfizer expects 2025 adjusted EPS to be in a ...
Pfizer Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%
Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...
Pfizer (NYSE:PFE) Is Increasing Its Dividend To $0.43
Pfizer Inc.'s ( NYSE:PFE) periodic dividend will be increasing on the 7th of March to $0.43, with investors receiving 2.4% ...
Insider Monkey on MSN2d
Pfizer (PFE) Is Too Cheap To Ignore
Pfizer just raised its dividend by 2.4% to $0.43, giving investors something to cheer about despite the stock’s lackluster ...
STAT4d
Pfizer’s blockbuster Ibrance slows tumor progression in another type of breast cancer
The efficacy data could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis.
Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)
Pfizer has a diversified portfolio, including successful vaccines and promising new drugs. Read more to see why I upgrade PFE ...
The Motley Fool2d
Is Pfizer a Millionaire Maker?
Despite recent headwinds, Pfizer is likely to gain value over the long term. Its stock also pays a dividend, and with a ...
STAT8d
Pfizer’s abrupt withdrawal of sickle cell drug Oxbryta called ‘tone deaf’ at ASH conference
SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a ...